Journal
CANCER LETTERS
Volume 476, Issue -, Pages 1-12Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2020.02.002
Keywords
Glioma; Immunotherapy; Checkpoint; Oncolytic virus; Vaccine
Categories
Funding
- National Natural Science Foundation of China [81472693, 81873635]
- Natural Science Foundation of Hunan Province [2019JJ50963]
Ask authors/readers for more resources
Gliomas are intrinsic brain tumors that originate from neuroglial progenitor cells. Conventional therapies, including surgery, chemotherapy, and radiotherapy, have achieved limited improvements in the prognosis of glioma patients. Immunotherapy, a revolution in cancer treatment, has become a promising strategy with the ability to penetrate the blood-brain barrier since the pioneering discovery of lymphatics in the central nervous system. Here we detail the current management of gliomas and previous studies assessing different immunotherapies in gliomas, despite the fact that the associated clinical trials have not been completed yet. Moreover, several drugs that have undergone clinical trials are listed as novel strategies for future application; however, these clinical trials have indicated limited efficacy in glioma. Therefore, additional studies are warranted to evaluate novel therapeutic approaches in glioma treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available